Browsing Tag
Grünenthal
2 posts
Mesoblast (ASX: MSB) clears key treatment milestone ahead of mid-2027 back pain trial readout
Mesoblast has treated at least 300 patients in MSB-DR004, starting the final 12-month clock towards a mid-2027 readout and potential United States filing. The milestone strengthens execution visibility, but it does not provide new efficacy data.
Bayer to sell men’s health product Nebido to Grünenthal in €500m deal
Bayer has agreed to sell Nebido (testosterone undecanoate), its men’s health product, to German pharma company Grünenthal for…